A randomized, double-blind, placebo-controlled clinical trial of Shufeng Zhike Mixture in the treatment of post-infectious cough (fengxie loves the lung syndrome)

West China Hospital of Sichuan University0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1. Meet the diagnostic criteria of Western medicine for post-infection cough;
•2. In line with the diagnostic criteria of Chinese medicine for cough, wind and pathogenic love of the lung syndrome;
•3. Cough severity score >=40;
•4. Cough duration 3-8 weeks;
•5. Age 18-65 years old;
•6. Informed consent and signed the informed consent form.

•1. Patients with cough variant asthma, upper airway cough syndrome, eosinophilic bronchitis, gastroesophageal reflux cough, chronic bronchitis and other causes of cough;
•2. Patients with severe pulmonary diseases (such as chronic obstructive pulmonary disease, lung cancer, tuberculosis);
•3. Patients who have taken angiotensin-converting enzyme inhibitors within the past 2 months;
•4. Patients with abnormal behavior or mental illness;
•5. Patients who smoke or quit smoking for less than three months;
•6. Combined with serious primary diseases of cardiovascular and cerebrovascular, liver, kidney and hematopoietic system, or serious diseases affecting their survival, such as tumor or AIDS; or mentally or legally disabled patients; 7. ALT>1.5 times normal upper limit of reference value, and/or serum creatinine > upper limit of normal reference value;
•8. White blood cells <3.0x10^9/L or >10.0x10^9/L, and/or neutrophil classification>80%;
•9. Patients who have taken drugs similar to those of the experimental drug in the past 1 month;
•10. Women who are pregnant or planning to become pregnant, women who are breastfeeding; those with allergic constitution or known ingredients of the drug; those who have participated in clinical trials of other drugs in the past 3 months.

发起方

West China Hospital of Sichuan University